Product Images Lenalidomide

This is a description of a medication called Lenalidomide available in capsules. The pharmacist is instructed to dispense a medication guide provided to each patient. Each capsule contains 15 mg of lenalidomide, and the recommended dosages are available in the prescribing information. It is warned that there is potential for human birth defects. The medication needs to be stored between 20°C to 25°C and excursions permitted to 15°C to 30°C only. The website, Camber Pharmaceuticals, provides a medication guide, and there's a U.S. contact number provided. Camber Pharmaceuticals manufactures the medication for Hetero Labs Limited, an Indian-based pharmaceutical company.*

This is a medication description for Lenalidomide, enclosed in a capsule. It contains 2.5 mg of the medicine. The usual dosage must be checked in the prescribing information. The capsules should be stored at room temperature, between 20°C to 25°C, with permitted excursions to 15°C to 30°C. There is a potential for birth defects, and it is a prescription-only medication. The medication guide is available on the manufacturer's website. The product is manufactured by Hetero Labs Limited in India and is distributed by Camber Pharmaceutical in Piscataway, NJ.*

This is a medication guide for Lenalidomide capsules. It is meant to be dispensed by a pharmacist to each patient separately. The medication has a warning for potential birth defects. Each capsule contains 20mg of the drug and the dosage information can be found in the prescribing information. The capsules should be stored at a controlled room temperature between 20°C and 25°C. The medication guide is available at camberpharma.com/medication-guides. The manufacturer is Camber Pharmaceuticals, Inc. and their contact information is available on the package.*

This text includes information about a medication called Lenalidomide available in capsule form with 25 mg strength. The pharmacist is instructed to dispense the medication guide separately to each patient. It warns about the potential for human birth defects and provides the U.S. contact number. The manufacturing company is Camber Pharmaceuticals. Store the medication at a temperature between 20-25°C. Dosage instructions are in the prescribing information. The other text appears to be misread and includes errors.*

This is a medication named Lenalidomide, which comes in capsule form containing 5 mg of the medication. It is prescribed by a physician and dispensed by pharmacists to patients with a provided medication guide. The medication has warnings of potential birth defects, so caution should be taken if pregnant or planning to become pregnant. The medication guide is available online, and the manufacturer is Camber Pharmaceuticals with a contact number for the US customers. It should be stored at room temperature between 20-25°C and has a usual dosage mentioned that can be found in the prescribing information provided. It is manufactured in India by Hetero Labs Limited.*

This text presents survival probability data and progression-free survival duration for different treatment groups. It includes the percentage of subjects surviving, logarithmic values, and the number of subjects at risk. It also shows the percentage of events for progression-free survival in each treatment group.*

This data represents the results of a clinical trial comparing Lenalidomide versus Placebo in terms of progression-free survival. The hazard ratio along with its 95% confidence interval is also provided. The median (with its corresponding 95% confidence interval) of progression-free survival for Lenalidomide and Placebo groups is given in months. Lastly, the table displays the number of subjects at risk and the percentage of progression-free survival events in each group.*

This appears to be a medical document comparing the survival probability of two treatments, Lenalidarrude and Hlaoe, for some kind of condition. The document includes a table with numerical data on the number of events and subjects at risk, and a chart showing the progression-free survival over time. The quality is poor and the text is difficult to read, but the document seems to be intended for medical professionals or researchers in the field.*

This is a statistical output of a clinical trial evaluating the efficacy of Lenalidomide and Dex for the treatment of a certain condition. The figure shows a Kaplan-Meier curve illustrating the proportion of subjects with time to progression plotted against time in months. The numerical outcome of the trial is indicated by the hazard ratio (HR), which is 0.285 with a 95% confidence interval (CI) of 0.210-0.386. The statistical significance of the outcome is also shown with a Log Rank p-value of less than 0.001. No further information is available.*

The text shows a graphical representation of the proportion of subjects in a study, along with data on their time to progression (in months) and treatment with Lonalidomide/Dex. The hazard ratio is reported as 0.324 with a 95% confidence interval of 0.240-0.438, and the log-rank p-value is less than 0.001.*